Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Oculis Holding AG OCS

Healthcare
Oculis Holding AG is a Switzerland-based company primally engaged in biotechnology sector. The Company is focused on the development of eye disease treatment for ophthalmology. It includes OCS-01, based on the OPTIREACH technology, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED) in a form of a single chain antibody... see more

Recent & Breaking News (NDAQ:OCS)

Oculis to Present at OIS Retina Innovation Summit

GlobeNewswire July 19, 2023

Oculis to Host an R&D Retina Day to Showcase Clinical Programs Targeting Diabetic Macular Edema and Other Retina Diseases on Tuesday, July 11, 2023

GlobeNewswire June 26, 2023

Oculis Announces Partial Exercise of Underwriters' Option to Purchase Additional Ordinary Shares

GlobeNewswire June 13, 2023

Oculis Wins the 2023 Icelandic Knowledge Award from the Icelandic Association of Business and Economics

GlobeNewswire June 12, 2023

Stonegate Healthcare Partners Announces Publishing of a Thematic Report - Beyond VEGF: Therapies Revolutionizing Diabetic Eye Disease

Newsfile June 1, 2023

Oculis to Participate in Jefferies Healthcare Conference

GlobeNewswire June 1, 2023

Oculis Announces Pricing of $40.25 Million Public Offering of Ordinary Shares

GlobeNewswire May 31, 2023

Oculis Announces Launch of Proposed Public Offering of Ordinary Shares

GlobeNewswire May 30, 2023

Oculis to Participate and Present at Upcoming EuDES Meeting

GlobeNewswire May 24, 2023

Oculis Announces Positive Top Line Results from DIAMOND Stage 1 Phase 3 Trial in Diabetic Macular Edema with OCS-01 Eye Drops

GlobeNewswire May 22, 2023

Oculis Co-founders Selected as Finalists in European Inventor Award 2023

GlobeNewswire May 11, 2023

Oculis Opens New Offices in the US and Expands its US Team by Appointing Dr. Fang Li as Senior Vice President, Regulatory Affairs

GlobeNewswire April 26, 2023

Oculis to Participate at Upcoming Investor Conferences

GlobeNewswire April 5, 2023

Oculis to Host Conference Call on April 13, 2023 to Discuss Late-Stage Pipeline and Near-Term Clinical Milestones

GlobeNewswire April 4, 2023

Oculis to Ring Nasdaq Stock Market Opening Bell in Celebration of its Successful Listing

GlobeNewswire March 22, 2023

Oculis Completes Enrollment in Phase 3 OCS-01 OPTIMIZE Trial

GlobeNewswire March 16, 2023